Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2305]

Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )

ASH 2020: Targeted therapies in r/r multiple myeloma

Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar

ASH 2020: Targeted therapies in r/r multiple myeloma ( Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar )

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment

Prof Monica Bocchia - University of Siena, Siena, Italy

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment ( Prof Monica Bocchia - University of Siena, Siena, Italy )

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including...

Dr Shaji Kumar and Dr Wenming Chen

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective ( Dr Shaji Kumar and Dr Wenming Chen )

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the...

Dr Jorge Cortes - Augusta University, Augusta, USA

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation ( Dr Jorge Cortes - Augusta University, Augusta, USA )

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D)...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin...

Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia

$Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data ( Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia )$

Five year update of ECHELON-1 for classical Hodgkin lymphoma

Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil

Five year update of ECHELON-1 for classical Hodgkin lymphoma ( Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil )

Blinatumomab and oral TKIs for the treatment of Ph ALL

Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA

Blinatumomab and oral TKIs for the treatment of Ph ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL

Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )

Real world management of multiple myeloma patients

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5...

Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results ( Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany )

More from ecancer